Compared to healthy controls, pre-treatment MDD patients exhibited significantly higher expression levels of PPAR-γ (F = 6.213, p < 0.001) and FOS (F = 2.775, p = 0.023) and lower expression levels of JUN (F = 2.631, p = 0.029). The gene discussed is FOS; the disease is major depressive disorder.